Report Details

Global Colorectal Cancer Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2019 to 2025

ID : 7745293
Date : May 2019
Pages : 211 Pages
Industry : Pharmaceutical and Healthcare


Colorectal cancer is also known as bowel cancer. It refers to the abnormal growth of the cells in colon and rectum due to cancer. Colorectal cancer starts either in the colon and rectum. Cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain.



Global colorectal cancer market is driven by some of the major factors such as increasing prevalence of colorectal cancer, technological advancements in the cancer therapy, aging population, and raise in consumer awareness about colorectal cancers. However, high costs of screening tests and drugs, lack of knowledge are some of the restraints that are hampering the growth of the global colorectal cancer drugs market.



The global colorectal cancer drugs market is segmented by therapy, drug class, distribution channel, and regions.



On the basis of therapy, global colorectal cancer drugs market is segmented as

Adjuvant chemotherapy
Palliative chemotherapy
Immuno therapy
Neo adjuvant chemotherapy


On the basis of drug class, global colorectal cancer drugs market is segmented as

Capecitabine Xeloda
Irinotecan Camptosar
Fluorouracil 5-FU, Adrucil
Trifluridine/tipiracil TAS-102, Lonsurf
Oxaliplatin Eloxatin
Others


Some common treatment regimens using these drugs include:

5-FU
Capecitabine, an oral form of 5-FU
5-FU with leucovorin Wellcovorin, a vitamin that improves the effectiveness of 5-FU
FOLFIRI: 5-FU with leucovorin and irinotecan
FOLFOX: 5-FU with leucovorin and oxaliplatin
Irinotecan alone
XELOX/CAPEOX: Capecitabine with oxaliplatin
XELIRI/CAPIRI: Capecitabine with irinotecan


On the basis of distribution channel, the global colorectal cancer drugs market is segmented as

Retail Pharmacies
Hospital Pharmacies
Others


Colorectal cancer is the third most common cancer in the world. Huge government initiatives taken by the nations are booming up the growth of the colorectal cancer drugs treatment market globally. Biologics such as Zaltrap Ziv-Aflibercept, Erbitux Cetuximab, Avastin Bevacizumab are using rapidly for the treatment for colorectal cancer that are used as a targeted therapy and they acts only on the malignant cells. Market players in the colorectal cancer drugs market forming strategic alliances and partnerships to increase their market share.



Geographically, global colorectal cancer treatment market is segmented into five key regions such as Latin America, North America, Asia-Pacific, Europe and The Middle East and Africa. North America expected to grow at significant rate in colorectal cancer drugs market owing to the growing incidence of colorectal cancer and widespread awareness about early diagnosis and treatment of colorectal cancer. Asia Pacific region expected to have rapid growth in the market during the forecast period owing to huge population densities and high incidence of colorectal cancer in countries such as India and China.



Some of the players in the colorectal cancer drugs market are Amgen Inc. U.S, Bristol-Myers Squibb Company U.S., F. Hoffmann-La Roche Ltd. Switzerland, Bayer AG Germany, Merck & Co., Inc. U.S., and Sanofi France to name a few.



In Aug 2016, Sanofi’s Zaltrap received U.S. FDA approval to use with FOLFIRI to treat adult patients having colorectal cancer


In May 23, 2014, the U.S. Food and Drug Administration FDA approved for Amgen’s Vectibix panitumumab for use in combination with FOLFOX, to treat metastatic colorectal cancer


In Sept. 16, 2013, Genentech received U.S. FDA approval for the first generic version of Xeloda, to treat cancer of the colorectal cancer


In Sept 2012, The USFDA approved Stivarga regorafenib Bayer tablets to treat patients with collateral cancer


Report Outline:



The report provides granular level information about the market size, regional market share and forecast from 2019-2025
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. Executive summary
2. Global Colorectal Cancer Drugs Market Introduction
2.1. Global Colorectal Cancer Drugs Market– Taxonomy
2.2. Global Colorectal Cancer Drugs Market–Definitions
2.2.1. Drug Type
2.2.2. Therapy
3. Global Colorectal Cancer Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Colorectal Cancer Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Colorectal Cancer Drugs Market– Recent Market Introductions
4. Global Colorectal Cancer Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 – 2025
4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
4.2. Year-over-Year Y-o-Y Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Colorectal Cancer Drugs Market Forecast, By Therapy, 2014 - 2018 and Forecast, 2019 - 2025
5.1. Adjuvant Chemotherapy
5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Palliative Chemotherapy
5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Immuno Therapy
5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. Neo Adjuvant Chemotherapy
5.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
6. Global Colorectal Cancer Drugs Market Forecast, By Drug Type, 2014 - 2018 and Forecast, 2019 - 2025
6.1. Capecitabine
6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Irinotecan
6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Fluorouracil
6.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
6.4. Trifluridine/tipiracil
6.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.4.3. Market Opportunity Analysis
6.5. Oxaliplatin
6.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.5.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.6.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.6.3. Market Opportunity Analysis
7. Global Colorectal Cancer Drugs Market Forecast, By End User, 2014 - 2018 and Forecast, 2019 - 2025
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
8. Global Colorectal Cancer Drugs Market Forecast, By Region, 2014 - 2018 and Forecast, 2019 - 2025
8.1. North America
8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.5.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Region, 2019 – 2025
9. North America Colorectal Cancer Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
9.1.1. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.1.1. Adjuvant Chemotherapy
9.1.1.2. Palliative Chemotherapy
9.1.1.3. Immuno Therapy
9.1.1.4. Neo Adjuvant Chemotherapy
9.1.2. Drug Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.2.1. Capecitabine
9.1.2.2. Irinotecan
9.1.2.3. Fluorouracil
9.1.2.4. Trifluridine/tipiracil
9.1.2.5. Oxaliplatin
9.1.2.6. Others
9.1.3. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.3.1. Retail Pharmacies
9.1.3.2. Hospital Pharmacies
9.1.3.3. Online Pharmacies
9.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn Y-o-Y Growth % and Market Share %
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2019 – 2025
9.1.6. North America Colorectal Cancer Drugs Market Dynamics – Trends
10. Europe Colorectal Cancer Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
10.1.1. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.1.1. Adjuvant Chemotherapy
10.1.1.2. Palliative Chemotherapy
10.1.1.3. Immuno Therapy
10.1.1.4. Neo Adjuvant Chemotherapy
10.1.2. Drug Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.2.1. Capecitabine
10.1.2.2. Irinotecan
10.1.2.3. Fluorouracil
10.1.2.4. Trifluridine/tipiracil
10.1.2.5. Oxaliplatin
10.1.2.6. Others
10.1.3. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.3.1. Retail Pharmacies
10.1.3.2. Hospital Pharmacies
10.1.3.3. Online Pharmacies
10.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2019 – 2025
10.1.6. Europe Colorectal Cancer Drugs Market Dynamics – Trends
11. Asia-Pacific Colorectal Cancer Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
11.1.1. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.1.1. Adjuvant Chemotherapy
11.1.1.2. Palliative Chemotherapy
11.1.1.3. Immuno Therapy
11.1.1.4. Neo Adjuvant Chemotherapy
11.1.2. Drug Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.2.1. Capecitabine
11.1.2.2. Irinotecan
11.1.2.3. Fluorouracil
11.1.2.4. Trifluridine/tipiracil
11.1.2.5. Oxaliplatin
11.1.2.6. Others
11.1.3. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.3.1. Retail Pharmacies
11.1.3.2. Hospital Pharmacies
11.1.3.3. Online Pharmacies
11.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn,
Y-o-Y Growth %, and Market Share %
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2019 – 2025
11.1.6. Asia-Pacific Colorectal Cancer Drugs Market Dynamics – Trends
12. Latin America Colorectal Cancer Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
12.1.1. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.1.1. Adjuvant Chemotherapy
12.1.1.2. Palliative Chemotherapy
12.1.1.3. Immuno Therapy
12.1.1.4. Neo Adjuvant Chemotherapy
12.1.2. Drug Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.2.1. Capecitabine
12.1.2.2. Irinotecan
12.1.2.3. Fluorouracil
12.1.2.4. Trifluridine/tipiracil
12.1.2.5. Oxaliplatin
12.1.2.6. Others
12.1.3. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.3.1. Retail Pharmacies
12.1.3.2. Hospital Pharmacies
12.1.3.3. Online Pharmacies
12.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2019 – 2025
12.1.6. Latin America Colorectal Cancer Drugs Market Dynamics – Trends
13. Middle East & Africa Colorectal Cancer Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
13.1.1. Therapy Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.1.1. Adjuvant Chemotherapy
13.1.1.2. Palliative Chemotherapy
13.1.1.3. Immuno Therapy
13.1.1.4. Neo Adjuvant Chemotherapy
13.1.2. Drug Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.2.1. Capecitabine
13.1.2.2. Irinotecan
13.1.2.3. Fluorouracil
13.1.2.4. Trifluridine/tipiracil
13.1.2.5. Oxaliplatin
13.1.2.6. Others
13.1.3. End User Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.3.1. Retail Pharmacies
13.1.3.2. Hospital Pharmacies
13.1.3.3. Online Pharmacies
13.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
13.1.4.1. Gulf Cooperation Council GCC Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2019 – 2025
13.1.6. MEA Colorectal Cancer Drugs Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. Amgen Inc. U.S
14.2.2. Bristol-Myers Squibb Company U.S.
14.2.3. F. Hoffmann-La Roche Ltd. Switzerland
14.2.4. Bayer AG Germany
14.2.5. Merck & Co., Inc. U.S.
14.2.6. Sanofi France
15. Research Methodology
16. Key Assumptions and Acronyms


Please fill the following form to know more details about this Report




RELATED PRODUCTS



CHOOSE A FORMAT


  •  Single User Price : $ 4400
  •  Enterprise User License : $ 6600
  •  Corporate User License : $ 8900

Have A Question ?


  DOWNLOAD SAMPLE



TESTIMONIALS

I am completely satisfied with the information given in the sample pages of the report and I am waiting for the affirmative response from my peers and colleagues to purchase it.hey answered to all my queries promptly. I am highly satisfied!!
John Keats
We received a very quick response to all our queries on the RTLS report and we were also given a free consult with analyst for 15 minutes. It is refreshing (and increasingly rare) to have a new company go the extra mile to win the confidence of the customer
Ernest Hemingway
I would like to express my gratitude for the excellent service received this morning from the support team. They acknowledged my concern of adding me to the secondary user's list immediately. Thank you for this excellent, speedy and thoughtful service
Jacob Watson

CUSTOM RESEARCH

Still haven't found what you're looking for ?
Speak to our Custom Research Team